Related Experiment Videos
Levamisole in the treatment of chronic brucellosis
Abstract:
Ten patients with chronic brucellosis were treated with levamisole, 150mg daily for 3 consecutive days every week for 6 months. Patients were followed up for another 6 months after the end of treatment. By the end of the treatment period, patients improved clinically, their E rosettes showed a significant increase and specific leukocyte inhibition migration factor (LIF) was produced. By the end of the follow up period, all patients except one became symptom free, antiglobulin titers were very low or negative, E rosettes showed a further increase ranging to normal levels and specific LIF activity was not detected to most of the patients. Our results suggest that levamisole might prove to be beneficial in the treatment of chronic brucellosis.
Insights
Levamisole treatment for chronic brucellosis improved patient clinical symptoms and boosted immune markers like E rosettes. Most patients became symptom-free post-treatment, suggesting levamisole
Area of Science:
- Immunology
- Infectious Diseases
- Pharmacology
Background:
- Chronic brucellosis is a persistent bacterial infection with significant health implications.
- Current treatment options for chronic brucellosis may have limitations.
- Understanding immune system modulation in chronic infections is crucial.
Purpose of the Study:
- To evaluate the efficacy of levamisole in treating chronic brucellosis.
- To assess the impact of levamisole on immune responses in brucellosis patients.
Main Methods:
- Ten patients with chronic brucellosis received levamisole (150mg) for 3 consecutive days weekly over 6 months.
- Clinical assessments, E rosette assays, and leukocyte inhibition migration factor (LIF) tests were performed.
- Patients were followed for 6 months post-treatment.
Main Results:
- Clinical improvement was observed during treatment, with a significant increase in E rosettes and production of specific LIF.
- Post-treatment follow-up showed 90% of patients became symptom-free.
- Antiglobulin titers decreased, E rosettes normalized, and specific LIF activity diminished.
Conclusions:
- Levamisole demonstrated potential therapeutic benefits for chronic brucellosis.
- The drug appeared to restore immune function, contributing to symptom resolution.
- Further research is warranted to confirm levamisole's role in brucellosis management.